Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst sentiment is moderately bullish: Fourteen brokerages rate Teva a consensus “Moderate Buy,” with 12 buys, one hold and one sell. The average 12-month price target is $46.08, above the reported share price of $39.39.
• Teva reported quarterly revenue of $4.14 billion and earnings of $0.02 per share, while analysts expect full-year EPS of approximately $2.00.
• Insiders sold shares worth $14.6 million over the past three months, while institutional investors own 54.05% of the company and several large institutions recently increased their positions.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $46.08.

A number of equities analysts have recently issued reports on TEVA shares. Wall Street Zen cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Zacks Research cut shares of Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 20th. UBS Group upped their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a report on Friday, September 4th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 28th. Finally, Leerink Partners initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price objective for the company.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $39.39 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 1-year low of $18.88 and a 1-year high of $42.02. The firm has a market capitalization of $45.90 billion, a PE ratio of 65.65, a price-to-earnings-growth ratio of 3.66 and a beta of 0.89. The firm's 50 day simple moving average is $38.67 and its 200 day simple moving average is $35.27.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, analysts expect that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the business's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 374,959 shares of company stock worth $14,644,285 over the last three months. Corporate insiders own 0.54% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $9,126,000. WCM Investment Management LLC increased its position in Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Swiss National Bank raised its stake in Teva Pharmaceutical Industries by 28.7% during the 1st quarter. Swiss National Bank now owns 4,227,900 shares of the company's stock worth $127,344,000 after acquiring an additional 941,700 shares during the period. National Pension Service raised its position in shares of Teva Pharmaceutical Industries by 4.9% during the 2nd quarter. National Pension Service now owns 2,406,013 shares of the company's stock valued at $81,516,000 after purchasing an additional 112,357 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at about $1,331,000. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world's largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva's portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.